By using our website you accept our cookies policy.Find out more

Biomedical catalyst 2017 round 3: feasibility studies

Funding details
Registration opens
31 Jul 2017, 00:00
11 Oct 2017, 12:00
£2 million
The Biomedical Catalyst is a partnership between Innovate UK and the Medical Research Council (MRC)
Support phone number
0300 321 4357

Micro, small or medium-size UK companies can apply for a share of £2 million to work alone or with others on solving healthcare challenges.

The aim of this competition is to support the development of innovative healthcare technologies and processes. These may include:

  • disease prevention and proactive management of health and chronic conditions
  • earlier and better detection and diagnosis of disease, leading to better patient outcomes
  • tailored treatments that either change the underlying disease or offer potential cures

The biomedical catalyst has 4 types of funding award designed to support small to medium enterprises (SMEs) that are developing a product or process. It helps them progress from initial concept through to late-stage development.

Each type of award has a different scope. You should apply only if your project fits a specific competition scope.

This is a feasibility competition. They are looking to fund projects that explore and evaluate the commercial potential of innovative scientific ideas by:

  • reviewing research evidence and identifying possible applications
  • assessing business opportunities
  • investigating the intellectual property position
  • validating initial concepts or existing pre-clinical work through experimental studies
    identifying areas for further development

They expect projects to range in size up to £200,000. Projects should last no longer than 12 months.

You can find out more on the competition page here.

Related Funding Opportunities

Opportunities for UK Advanced Therapies sector through Industrial Strategy Challenge Fund

A £146 million commitment over the next four years to support the development of technologies and facilities for the manufacture of innovative medicin